Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PSTX | US
-0.03
-1.14%
Healthcare
Biotechnology
30/06/2024
04/10/2024
2.61
2.52
2.64
2.52
Poseida Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1 an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1 which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors including breast colorectal lung ovarian pancreatic and renal cancers. In addition the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1 an allogeneic off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further it is developing P-PSMA-101 an allogeneic CAR-T product candidate for treating mCRPC. Additionally the company engages in the development of P-OTC-101 a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101 a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101 a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA Inc. F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
41.3%1 month
71.1%3 months
76.0%6 months
85.1%-
-
4.63
1.38
0.28
-1.24
1.44
-
-112.86M
253.52M
253.52M
-
-122.27
-
29.80
-115.00
13.17
5.48
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.09
Range1M
1.40
Range3M
1.61
Rel. volume
1.01
Price X volume
1.37M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Editas Medicine Inc | EDIT | Biotechnology | 3.38 | 278.77M | 4.97% | n/a | 16.68% |
uniQure N.V | QURE | Biotechnology | 5.65 | 275.14M | 24.45% | n/a | 550.36% |
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.63 | 269.88M | 0.87% | n/a | 1.55% |
Genfit SA | GNFT | Biotechnology | 5.3861 | 268.80M | 4.67% | 13.90 | 104.08% |
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Progenitor Inc | PGEN | Biotechnology | 0.9 | 263.38M | -6.82% | n/a | 14.69% |
Mersana Therapeutics Inc | MRSN | Biotechnology | 2.12 | 260.07M | 3.92% | n/a | 383.37% |
ChromaDex Corporation | CDXC | Biotechnology | 3.38 | 256.65M | -2.59% | n/a | 10.17% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6058 | 249.09M | 0.30% | n/a | 1.47% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.24 | 0.76 | Cheaper |
Ent. to Revenue | 1.44 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.63 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 76.01 | 74.67 | Par |
Debt to Equity | 1.38 | -1.82 | Expensive |
Debt to Assets | 0.28 | 0.26 | Par |
Market Cap | 253.52M | 3.73B | Emerging |